Feb 7 |
I-Mab to divest Chinese assets amid rising geopolitical tensions
|
Feb 7 |
UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US
|
Feb 7 |
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
|
Nov 19 |
Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%
|
Nov 6 |
I-Mab Announces Participation at Jefferies and Piper Conferences in November
|
Nov 2 |
I-Mab gains FDA breakthrough tag for kidney disease therapy
|
Nov 2 |
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
|
Nov 1 |
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
|